Oxford, UK – 18 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today publishes its interim management statement for the period from 1 January to 17 May 2011. Read More
— Diagnostic rights secured for Investigational New Drug application — Oxford, UK – 4 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford, UK – 3 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson’s disease (PD) will be… Read More
Oxford, UK – 21 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today announces that by mutual agreement, its Chairman, Dr Alan Kingsman, will leave the Board of Oxford BioMedica… Read More
— Second of four products in Phase I/II ocular programme partnered with sanofi-aventis approved to enter clinical development — Oxford, UK –… Read More
— Immune Response Surrogate Algorithm Shown to be a Significant Predictor of Clinical Benefit — Oxford, UK – 15 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Click here to download the full 2010 preliminary results statement.Click here to download the 2010 results slide deck.Click… Read More
Oxford, UK – 9 February 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today announces the appointment of James Christie, BSc, MBA to the newly created role of Head of… Read More
— Support for Oxford BioMedica’s five LentiVector® technology-based programmes — — UK production facility in Oxford to… Read More
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More